This episode of Endocrine Deep Dives explores the diagnostic nuances of the adrenocorticotropic hormone stimulation test. We break down how this core dynamic assay differentiates primary adrenal insufficiency from secondary adrenal insufficiency by evaluating cortisol reserve. The discussion covers standard two hundred fifty microgram protocols, limitations in early pituitary disease, and the clinical utility of baseline morning cortisol and dehydroepiandrosterone sulfate. Finally, we analyze critical updates to assay-specific diagnostic cutoffs required by modern monoclonal testing platforms.

This episode delivers a rigorous evaluation of hemoglobin A1c pitfalls where the marker fails to accurately reflect true glycemia. We examine how altered erythrocyte turnover, hemoglobin variants, and specific clinical conditions distort glycation dynamics independently of plasma glucose levels. Listeners will learn to identify when to suspect inaccurate A1c readings, how conditions like advanced chronic kidney disease or hemoglobinopathies confound data, and when to utilize alternative biomarkers like fructosamine or continuous glucose monitoring metrics instead.

This episode delivers a definitive analysis of cystic fibrosis-related diabetes, the most common extra-pulmonary complication of cystic fibrosis. We explore its unique mixed pathophysiology, combining primary insulin insufficiency from progressive pancreatic fibrosis with fluctuating insulin resistance driven by chronic pulmonary inflammation. Listeners will learn to identify the clinical impact on nutritional status and lung function, understand why oral glucose tolerance tests are required for screening, and see why insulin remains the primary therapeutic intervention.

This episode delivers a clinical breakdown of HNF1B-MODY, also known as MODY5, which is characterized by heterozygous mutations in the hepatocyte nuclear factor-1-beta gene. We examine its systemic presentation, highlighting that renal cysts and diabetes syndrome frequently precede carbohydrate intolerance. Listeners will learn to identify structural renal anomalies, genital tract abnormalities, and pancreatic exocrine insufficiency, while understanding why these patients experience early progressive renal failure and require early insulin therapy due to a profound hepatic insulin resistance.

This episode delivers a precise analysis of GCK-MODY, also known as MODY2, a genetic form of diabetes caused by heterozygous inactivating mutations in the glucokinase gene. We explore how this molecular defect alters the pancreatic glucose sensor, shifting the glycemic threshold upward. Listeners will learn why patients exhibit lifelong, stable, mild fasting hyperglycemia that rarely progresses, why microvascular complications are exceptionally uncommon, and why pharmacological management is typically unnecessary outside of pregnancy.

This episode of Endocrine Deep Dives explores HNF4A MODY, also known as MODY 1, a rare form of monogenic diabetes caused by mutations in the hepatocyte nuclear factor 4 alpha gene. We break down its distinct clinical phenotype, including macrosomia and neonatal hypoglycemia at birth, followed by progressive beta cell dysfunction later in life. We also discuss diagnostic screening criteria and why these patients show exquisite sensitivity to low dose sulfonylureas.

This episode of Endocrine Deep Dives explores HNF1A MODY, or MODY 3, the most common form of monogenic diabetes. We examine its characteristic clinical presentation, marked by progressive beta cell dysfunction, a low renal threshold for glucose, and a lack of pancreatic autoantibodies. We discuss the importance of genetic testing to differentiate it from type 1 and type 2 diabetes and outline why low dose sulfonylureas are the preferred first line pharmacological treatment.

This episode breaks down postmenopausal ovarian hyperthecosis, a benign but impactful condition where altered ovarian cells overproduce androgens. We explore how postmenopausal hormonal shifts and insulin resistance synergize to drive severe virilization, hirsutism, and heightened metabolic or endometrial risks. Learn to differentiate this slow-progressing disorder from aggressive ovarian tumors using precise diagnostic imaging and lab panels. Finally, we review management strategies, from definitive surgical oophorectomy to targeted medical therapies and metabolic interventions.

This episode explores the biological mechanisms and medical management of infertility in polycystic ovary syndrome, focusing on how hormonal imbalances and insulin resistance cause follicular arrest. We evaluate pharmacological interventions, highlighting why letrozole has surpassed clomiphene citrate as the premier first-line agent for ovulation induction. The discussion covers adjunctive therapies like metformin, surgical options including ovarian drilling, and optimized advanced reproductive technology protocols designed to minimize ovarian hyperstimulation syndrome risk during in vitro fertilization.

In this episode, we unpack premature ovarian insufficiency, exploring why normal ovarian function ceases before age forty. We break down the clinical diagnostic criteria, specifically tracking elevated follicle-stimulating hormone levels and menstrual irregularities. From genetic factors like Turner syndrome to autoimmune and iatrogenic causes, we map out the underlying etiologies. Finally, we discuss the systemic long-term health risks of early estrogen loss, such as osteoporosis, and review hormone replacement therapy strategies to safeguard patient health.